Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Suffers Grim Q3, But Management Points To Future Growth Drivers

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s revenues fell 16% in the third quarter, as the pharma giant absorbed exclusivity losses including the loss of Lipitor, but management tried its best to highlight long-term growth drivers during a Nov. 1 conference call.

You may also be interested in...



Emerging Markets Earnings Roundup: Pfizer (Part 4)

Pfizer considers the structure of its pharma operations in emerging markets as the dust begins to settle from its spin-off of its animal health business and the sale of its nutrition business.

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.

Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs

Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS073476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel